Gilead's HIV combo wins EU approval; CTI moves toward FDA with Baxalta-partnered cancer drug;

@FierceBiotech: With Pfizer and Allergan set for a $160B megamerger, what becomes of R&D? Report | Follow @FierceBiotech

@JohnCFierce: So Ian Read remains CEO. Gets $AGN at a pretty decent price, Gets his Irish domicile. Looking for $2B in cuts. Read must be pretty chuffed. | Follow @JohnCFierce

@DamianFierce: I thought Ian Read would be taller. Item | Follow @DamianFierce

> Genvoya, Gilead Sciences' ($GILD) combination HIV treatment, won European approval. The FDA signed off on the drug earlier this month. Item

> CTI BioPharma ($CTIC) began a rolling FDA submission for pacritinib, its Baxalta ($BXLT)-partnered treatment for myelofibrosis. The company expects to complete its application by the end of the year. News

> Chinese biotech Generon is partnering with the Mayo Clinic on a Phase II study testing its investigational F-652 in alcoholic hepatitis. More

Medical Device News

@FierceMedDev: ICYMI Friday: Bard to buy Liberator for $181M to improve access to home care market. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Scientific earns CE mark for second-gen Watchman implant to prevent stroke. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI Friday: Cancer diagnostics company closes up shop after 6-year FTC investigation. Article | Follow @EmilyWFierce

> Startup gets $36.5M to conduct U.S. pivotal trial for novel endoscopic weight loss device. More

> CardioDiagnostics gets in on patient monitoring with plans for $7M fundraise. Article

> Mindray Medical shells out $25M to settle pulse oximeter patent battle with Masimo. Story

Pharma News

@FiercePharma: CBN: Multinational drugmakers face uphill battle in China. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: UPDATED: Pfizer finally gets its inversion with $160B Allergan megamerger agreement. Article | Follow @CarlyHFierce

> Takeda's Velcade successor gets quick FDA approval. Item

> Amgen's Repatha scores an exclusive with CVS. Story

> Novartis scores new approvals for Cosentyx in Europe. Article

Animal Health News

> Virginia Tech preps dog trial of new method to improve glioblastoma treatment. Report

> Zoetis ups the ante in prevention with new flu vaccine and flea fighter for dogs. More

> Oasmia chairman is optimistic about animal health despite downsized IPO. Story

> Kuddly joins herd of veterinary apps with $1.5M seed round. Item

> Taco Bell joins fast food peers with cage-free egg pledge. Article

Biotech IT News

> Molecular Health raises $27M to advance data-crunching tech. News

> Illumina to make 5,000-genome autism database available through BaseSpace. Report

> Amazon shares landmark cancer genome data sets on cloud platform. Story

> FDA gives scientists freedom to tweet in long-awaited social media policy. Item

> AstraZeneca inks deal to install robots at new R&D facility. Article

Pharma Marketing News

> Amgen nabs another PCSK9 exclusive, this time with giant CVS. Report

> Better together? Savvy e-patients may make pharma marketing smarter. Story

> Teva goes for laughs in new social media campaign for COPD. Item

> AstraZeneca aims at a 'broader' target with services-based lung cancer effort. Article

> Healthcare ad and media agencies break into annual 'best workplaces' ranking. More

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i